# Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

> **NCT06241781** · PHASE2 · RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 83 (estimated)

## Conditions studied

- Adult

## Interventions

- **BIOLOGICAL:** GT101 injection
- **DRUG:** Gemcitabine injection

## Key facts

- **NCT ID:** NCT06241781
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-02
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06241781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06241781, "Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06241781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*